Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $24.28 USD
Change Today -0.19 / -0.78%
Volume 229.8K
SPNC On Other Exchanges
As of 12:02 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

spectranetics corp (SPNC) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/15 - $37.04
52 Week Low
06/2/14 - $20.96
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SPECTRANETICS CORP (SPNC)

Related News

No related news articles were found.

spectranetics corp (SPNC) Related Businessweek News

No Related Businessweek News Found

spectranetics corp (SPNC) Details

The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The company's vascular intervention product line includes crossing solutions, which support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions; peripheral atherectomy, a range of laser catheters for ablation of blockages in arteries above and below the knee; and coronary atherectomy and thrombectomy, which are aspiration for the treatment of blockages in the heart. Its primary crossing catheters include Quick-Cross, Quick-Cross Select, and Quick-Cross Extreme; the ELCA Laser Ablation Catheter for coronary atherectomy; and QuickCat aspiration catheter for thrombus management. The company's lead management product line comprises excimer laser sheaths, non-laser mechanical sheaths, and cardiac lead management accessories, such as Spectranetics Laser Sheath, and Lead Locking Device for the removal of pacemaker and defibrillator cardiac leads. It also offers the Stellarex DCB platform that is designed to treat peripheral arterial disease. The company sells its products in the United States, Canada, Europe, the Middle East, the Asia Pacific, Latin America, and Puerto Rico. The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, Colorado.

753 Employees
Last Reported Date: 02/27/15
Founded in 1984

spectranetics corp (SPNC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $966.6K
Chief Financial Officer and Vice President
Total Annual Compensation: $506.4K
Chief Operating Officer
Total Annual Compensation: $448.5K
Senior Vice President and General Counsel
Total Annual Compensation: $392.0K
Senior Vice President of Sales & Marketing fo...
Total Annual Compensation: $390.0K
Compensation as of Fiscal Year 2014.

spectranetics corp (SPNC) Key Developments

The Spectranetics Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:40 AM

The Spectranetics Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:40 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States.

The Spectranetics Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revises Earnings Guidance for the Year 2015

The Spectranetics Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $57,422,000 against $39,614,000 a year ago. Operating loss was $25,225,000 against $5,518,000 a year ago. Loss before taxes was $27,158,000 against $5,514,000 a year ago. Net loss was $27,305,000 or $0.65 per basic and diluted share against $5,661,000 or $0.14 per basic and diluted share a year ago. Cash flow used in operating activities was $22,874,000 against $8,359,000 a year ago. Non-GAAP net loss was $12,469,000 or $0.30 per share against $5,215,000 or $0.13 per share a year ago. For the year 2015, the company projects revenue in the range of $258 million to $265 million, an increase of $26 million to 29% over 2014, and are guiding to the low end of this range. Net loss for 2015 is projected to be within a range of $78 million to $82 million or $1.84 to $1.93 per share compared with $58 million to $62 million or $1.36 to $1.46 previously provided. Non-GAAP net loss for 2015 is projected to be within a range of $41.3 million to $45.3 million or $0.97 to $1.07 per share compared with $31.9 million to $35.9 million or $0.75 to $0.84 per share previously. Gross margin is unchanged and expected to be within a range of 74.5% to 75%. The revision reflects the potential impact of DCB products recently launched by competitors on the U.S. AngioSculpt business. As a result, Vascular Intervention revenue is anticipated to be at the low end of the previously provided 41% to 46% range. More specifically, AngioSculpt revenue is projected in the range of $59 million to $66 million, compared with previous outlook of $62 million to $66 million. The increased net loss consists of approximately $14 million of incremental spending associated with the Stellarex program and $6 million of increased costs related to litigation with TriReme Medical Inc.

The Spectranetics Corporation to Report Q1, 2015 Results on Apr 23, 2015

The Spectranetics Corporation announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on Apr 23, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPNC:US $24.28 USD -0.19

SPNC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $15.71 USD -0.225
AtriCure Inc $22.06 USD -0.24
Cardiovascular Systems Inc $27.72 USD -0.62
Endologix Inc $16.62 USD -0.01
Vascular Solutions Inc $32.77 USD -0.63
View Industry Companies

Industry Analysis


Industry Average

Valuation SPNC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.7x
Price/Book 7.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRANETICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at